iShares Nasdaq Biotechnology ETF Stock Forecast, Price & News

Wall Street analysts have given iShares Nasdaq Biotechnology ETF a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but iShares Nasdaq Biotechnology ETF wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

iShares Nasdaq Biotechnology ETF's stock was trading at $106.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IBB shares have increased by 43.2% and is now trading at $153.19.
View which stocks have been most impacted by COVID-19.

iShares Nasdaq Biotechnology ETF pays an annual dividend of $0.39 per share and currently has a dividend yield of 0.26%.
View iShares Nasdaq Biotechnology ETF's dividend history.

Shares of iShares Nasdaq Biotechnology ETF split on the morning of Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly issued shares were payable to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split.

Some companies that are related to iShares Nasdaq Biotechnology ETF include iShares MSCI Emerging Markets ETF (EEM), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR Bloomberg Barclays High Yield Bond ETF (JNK), SPDR Nuveen Barclays Short Term Municipal Bond ETF (SHM), SPDR Nuveen Barclays Municipal Bond ETF (TFI), DNP Select Income Fund (DNP), Direxion Daily Financial Bull 3X Shares (FAS), iShares MSCI Pacific ex Japan ETF (EPP), Nuveen Municipal Value Fund (NUV), Adams Diversified Equity Fund (ADX), PIMCO Corporate & Income Opportunity Fund (PTY), Goldman Sachs BDC (GSBD), Hercules Capital (HTGC), WisdomTree Emerging Markets High Dividend Fund (DEM) and Royce Value Trust (RVT).
View all of IBB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Nasdaq Biotechnology ETF investors own include NVIDIA (NVDA), The Walt Disney (DIS), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Cisco Systems (CSCO), Micron Technology (MU), Bank of America (BAC), Johnson & Johnson (JNJ) and PayPal (PYPL).

iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."

iShares Nasdaq Biotechnology ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include CHURCHILL MANAGEMENT Corp (0.11%), Valicenti Advisory Services Inc. (0.10%), Neville Rodie & Shaw Inc. (0.08%), Rye Brook Capital LLC (0.08%), Chesley Taft & Associates LLC (0.05%) and Winfield Associates Inc. (0.04%).

IBB stock was sold by a variety of institutional investors in the last quarter, including CHURCHILL MANAGEMENT Corp, M&R Capital Management Inc., Chesley Taft & Associates LLC, F&V Capital Management LLC, Neville Rodie & Shaw Inc., Golden Green Inc., Valicenti Advisory Services Inc., and Global Retirement Partners LLC.

IBB stock was bought by a variety of institutional investors in the last quarter, including HBW Advisory Services LLC, Rye Brook Capital LLC, Fulcrum Equity Management, Harbour Capital Advisors LLC, Crescent Capital Consulting LLC, Secure Asset Management LLC, Mcdonald Partners LLC, and Flagship Private Wealth LLC.

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IBB stock can currently be purchased for approximately $153.19.

iShares Nasdaq Biotechnology ETF has a market capitalization of $10.15 billion.